益气、活血、化痰法及其不同组合治疗方案对COPD大鼠干预作用研究
|
摘要
研究目的：
本课题旨在从细胞学、分子生物学和病理学三方面观察益气法、活血法、化痰法及其不同组合治疗方案对COPD大鼠气道炎症和气道重塑的影响和干预作用,从而对比和评价各不同治疗方法的疗效,并初步探讨其可能的作用机理,为中医药治疗COPD提供有效可靠的实验理论依据。
研究方法：
雄性SPF级SD大鼠90只,根据体重,随机分成9组(n=9)。同时,采用香烟熏结合气管内滴注脂多糖的方法建立COPD大鼠模型。
具体实验分组及用药如下：
①益气法组：给予益气组中药汤剂灌胃
②活血法组：给予活血组中药汤剂灌胃
③化痰法组：给予化痰组中药汤剂灌胃
④益气活血法组：给予益气活血组中药汤剂灌胃
⑤益气化痰法组：给予益气化痰组中药汤剂灌胃
⑥活血化痰法组：给予活血化痰组中药汤剂灌胃
⑦益气活血化痰法组：给予益气活血化痰组中药汤剂灌胃
⑧模型组：给予生理盐水灌胃
⑨空白组：给予生理盐水灌胃
给药时间及次数：各组从造模后第四天开始起给药,每日一次,直至造模结束第5天,用药共30天。
给药结束后,取材。采用细胞计数和HE染色法测量不同组别之间BALF中白细胞数量以及中性粒细胞、巨噬细胞和淋巴细胞的百分比,同时应用ELISA方法测定BALF中细胞因子IL-8和TNF-a的含量；免疫组化方法测量肺组织u-PA、TGF-p1和Elastin蛋白表达；显微镜下观测肺组织结构变化,并结合图像分析仪测量支气管总管壁和平滑肌厚度的改变。
研究结果：
1.各组BALF炎性细胞和细胞因子的变化
各组白细胞计数,巨噬细胞、中性粒细胞和淋巴细胞百分比,细胞因子IL-8和TNF-a的含量相比较,结果显示：白细胞计数,巨噬细胞、中性粒细胞百分比,细胞因子IL-8和TNF-a含量存在统计学意义(F=121.04, P=0.000<0.05; F=64.97, P=0.000<0.05; F=77.83, P=0.000<0.05; F=23.4, P=0.000<0.05; F=17.2, P=0.000<0.05),淋巴细胞不存在统计学意义(F=0.74,P=0.653>0.05)。各组之间白细胞计数、巨噬细胞、中性粒细胞百分比,细胞因子IL-8和TNF-α含量两两比较结果显示：模型组与空白组、益气活血化痰组、活血化痰组、益气活血组、益气化痰组和活血组比较；空白组同益气活血化痰组、活血化痰组、益气活血组、益气化痰组、化痰组、活血组及益气组相比较；益气活血化痰组同益气组、化痰组、活血组及益气化痰组相比较；益气活血组、活血化痰组同益气组、化痰组、活血组相比较；益气化痰组、活血组同益气组和化痰组相比较,白细胞计数,巨噬细胞百分比和中性粒细胞百分比,以及细胞因子IL-8和TNF-α含量,有明显差异,具有统计学意义(P<0.05)；但是益气活血化痰组、活血化痰组及益气活血组相比较,益气化痰组和活血组相比较,模型组、益气组及化痰组相比较,白细胞计数、巨噬细胞百分比和中性粒细胞百分比,细胞因子IL-8和TNF-α含量无明显差异(P>0.05)。
2.各组肺组织病理结构改变和支气管总管壁及平滑肌厚度的变化
HE染色观察各组形态学变化：正常对照组气道壁薄,气道平滑肌薄；气管粘膜上皮排列规整,无脱落、粘膜上皮纤毛完整,排列整齐、管壁平滑、官腔无狭窄；未见杯状细胞增生及鳞状上皮化生；肺泡形态正常,间隔完整；未见炎症细胞。模型组显示：支气管黏膜上皮纤毛粘连、倒伏,部分气道有脱落；上皮细胞变性、坏死；出现鳞状上皮化生；杯状细胞数量增加；气道粘膜下腺体肥大增生,出现浆液腺泡粘液腺化生,部分支气管黏膜及腺体出现萎缩;小气道管腔狭窄；支气管壁充血水肿,有淋巴细胞和浆细胞浸润,并有管壁淋巴小结形成；肺泡扩张,出现间隔变窄破裂；气道壁增厚,气道平滑肌的厚度和正常组比较增厚明显。除益气组和化痰组外,其余各治疗组与模型组相比较,肺组织结构较好,炎症浸润较轻,气道壁增厚、气道平滑肌厚度减轻。且改善程度同模型组相比较由低到高分别为：活血组、益气化痰组、益气活血组、活血化痰组、益气活血化痰组。
图像分析结果显示：各组支气管总管壁厚度和平滑肌厚度,结果显示都存在统计学意义(F=133.6,P=0.000<0.05；F=65.6,P=0.000<0.05)。各组之间支气管总管壁厚度和平滑肌厚度两两比较结果显示：模型组、益气组和化痰组同空白组、益气活血化痰组、活血化痰组、益气活血组、益气化痰组和活血组比较；益气活血化痰组、活血化痰组、益气活血组、益气化痰组及活血组同空白组相比较；活血组同和益气活血组、活血化痰组及益气化痰活血组相比较；益气化痰组同益气化痰活血组相比较,前者支气管总管壁厚度和平滑肌厚度增厚,差异有显著性,具有统计学意义(P<0.05)；但是益气活血化痰组、活血化痰组及益气活血组相比较,益气化痰组和活血组相比较,模型组、益气组及化痰组相比较,支气管总管壁厚度和平滑肌厚度无明显差异(P>0.05)。
3.各组肺组织u-PA、TGF-p1和Elastin表达的变化
采用Kruskal Wallis Test统计方法分析各组肺组织u-PA、TGF-β1和Elastin蛋白表达的变化,结果显示：各组肺组织u-PA、TGF-p1和Elastin蛋白表达,有明显差异,存在统计学意义(P=0.000<0.05)。各组之间肺组织u-PA、TGD-β1和Elastin蛋白表达两两比较结果显示：模型组、益气组及化痰组与正常对照组、益气活血化痰组、活血化痰组、益气活血组、益气化痰组及活血组相比较；益气化痰组及活血组同空白组相比较；活血组同和益气活血组、活血化痰组及益气化痰活血组相比较；益气化痰组同益气化痰活血组相比较,u-PA和TGF-β1蛋白表达增强,Elastin蛋白表达降低,,差异有显著性,具有统计学意义(P<0.05)；但是益气活血化痰组、活血化痰组及益气活血组相比较；益气化痰组和活血组相比较；模型组、益气组及化痰组相比较,u-PA、 TGF-β1和Elastin蛋白表达无明显差异(P>0.05)。
研究结论：
1.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可以抑制COPD大鼠BALF中性粒细胞聚集和巨噬细胞的增多和活化,减少细胞因子IL-8和TNF-α的分泌,达到缓解炎症反应的疗效。
2.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可以抑制COPD大鼠肺组织u-PA和TGF-β1表达的同时,增强Elastin表达。
3.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可以改善COPD大鼠支气管总管壁和平滑肌的厚度。
4.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可能是通过调节COPD大鼠肺组织u-PA、TGF-β1和Elastin的表达,达到干预和延缓COPD气道重塑的进程。
5.以益气、活血、化痰为主的三种治疗方法中,活血法更具疗效。
6.益气活血化痰组、活血化痰组和益气活血组的功效优于益气化痰组和活血组。
Objective:
To observe the intervention effect of Supplementing Qi, activating blood circulation, resolving phlegm and its combination regimens on airway inflammation and airway remodeling of COPD rats from the aspect of cytology, molecular biology and pathology. Through comparing and evaluating the efficacy of different treatment methods, we explore its possible mechanism action, and provide effective and reliable experimental basis for TCM on COPD.
Method:
90SD male rats were randomly divided into nine groups, meantime COPD rat model was established by intratracheal instillation of LPS and exposure to cigarette smoking daily. Specific subgroups and delivery are as follows:
①Supplementing Qi group:Administrated by decoction of supplementing Qi
②Activating blood circulation group:Administrated by decoction of activating blood circulation
③Resolving phlegm group:Administrated by decoction of resolving phlegm
④Supplementing Qi and activating blood circulation group:Administrated by decoction of Supplementing Qi and activating blood circulation
⑤Supplementing Qi and resolving phlegm group:Administrated by decoction of Supplementing Qi and resolving phlegm
⑥Activating blood circulation and resolving phlegm group:Administrated by decoction of activating blood circulation and resolving phlegm
⑦Supplementing Qi, activating blood circulation and resolving phlegm group: Administrated by decoction of Supplementing Qi, activating blood circulation and resolving phlegm
⑧The model group:Administrated by physiological saline
⑨The normal group:Administrated by physiological saline
Each group was administrated from the fourth day of molding, once a day, medication for30days.
Using cell counting and HE staining method to measure white blood cell count and the percentage of neutrophil, macrophage and lymphocyte in BALF, ELISA method to measure the content of cytokine IL-8and TNF-α in BALF, immunohistochemical method to measure the protein expression of u-PA, TGF-β1and Elastin in lung tissue, to observe the pulmonary tissue structural changes under the microscope, and measure the thickness of bronchial duct wall and smooth muscle with image analyzer.
Result:
1. The changes of inflammatory cells and cytokines in BALF
There was significant difference in different groups in white blood cell count,the percentage of neutrophil, macrophage and lymphocyte, and the content of cytokine IL-8and TNF-α in BALF (F=121.04, P=0.000<0.05; F=64.97, P=0.000<0.05; F=77.83, P=0.000<0.05; F=23.4, P=0.000<0.05; F=17.2, P=0.000<0.05). There was no significant difference in different groups in lymphocyte (F=0.74, P=0.653>0.05). The comparison of each two groups in white blood cell count,the percentage of neutrophil, macrophage and lymphocyte, and the content of cytokine IL-8and TNF-α in BALF show:the model group comparison with control group, supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; the control group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group, resolving phlegm group, and supplementing Qi group; supplementing Qi, activating blood circulation and resolving phlegm group comparison with activating blood circulation group, resolving phlegm group, supplementing Qi group, and supplementing Qi and resolving phlegm group; supplementing Qi and activating blood circulation group,activating blood circulation and resolving phlegm group comparison with activating blood circulation group, resolving phlegm group, supplementing Qi group; supplementing Qi and resolving phlegm group and activating blood circulation group comparison with resolving phlegm group and supplementing Qi group, there was significant difference (P<0.05). But comparison among supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, and supplementing Qi and activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood; the model group, resolving phlegm group, and supplementing Qi group was no significant difference (P>0.05).
2. The thickness changes of bronchial duct wall and smooth muscle
The morphologic changes of lung:the control group was normal, while the model group was showed significant pathological changes in the lung. While the other group except for resolving phlegm group, and supplementing Qi group, was improved in different level. The level of improvement from high to low was supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group.
The statistical results show:There was significant difference in different groups in the thickness of bronchial duct wall and smooth muscle (F=133.6, P=0.000<0.05; F=65.6, P=0.000<0.05). The comparison of each two groups in the thickness of bronchial duct wall and smooth muscle show:the model group, supplementing Qi group and resolving phlegm group comparison with control group, supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; the control group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; activating blood circulation group comparison with supplementing Qi and activating blood circulation group, activating blood circulation and resolving phlegm group, supplementing Qi, activating blood circulation and resolving phlegm group; supplementing Qi and resolving phlegm group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, there was significant difference (P<0.05). But comparison among supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, and supplementing Qi and activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood; the model group, resolving phlegm group, and supplementing Qi group was no significant difference (P>0.05).
3. The changes of protein expression of u-PA, TGF-β1and Elastin in lung tissue
The statistical results show:There was significant difference in different groups in the protein expression of u-PA, TGF-β1and Elastin of lung tissue (P=0.000<0.05). The comparison of each two groups in the protein expression of u-PA, TGF-β1and Elastin of lung tissue show:the model group, supplementing Qi group and resolving phlegm group comparison with control group, supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood circulation group comparison with the control group; activating blood circulation group comparison with supplementing Qi and activating blood circulation group, activating blood circulation and resolving phlegm group, supplementing Qi, activating blood circulation and resolving phlegm group; supplementing Qi and resolving phlegm group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, there was significant difference (P<0.05). But comparison among supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, and supplementing Qi and activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood; the model group, resolving phlegm group, and supplementing Qi group was no significant difference (P>0.05).
Conclusion:
1. The management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can inhibit accumulation, increase and activation of neutrophil and macrophage, reduce secretion of cytokine IL-8and TNF-α of BALF, and then relieve inflammation of COPD rat.
2. The management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can inhibit the expression of u-PA and TGF-β1,meanwhile enhance the expression of elastin in COPD rat lung tissue.
3. The management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can reduce thickening trend of bronchial duct wall and smooth muscle.
4. Tthe management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can intervent and delay COPD airway remodeling process, which maybe through the regulation of the expression of u-PA, TGF-β1and elastin in COPD rat lung tissue.
5. Activating blood circulation group was effective comparing with resolving phlegm group and supplementing Qi group.
6. The effect of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and activating blood circulation group is better than supplementing Qi and resolving phlegm group and activating blood circulation group.
本课题旨在从细胞学、分子生物学和病理学三方面观察益气法、活血法、化痰法及其不同组合治疗方案对COPD大鼠气道炎症和气道重塑的影响和干预作用,从而对比和评价各不同治疗方法的疗效,并初步探讨其可能的作用机理,为中医药治疗COPD提供有效可靠的实验理论依据。
研究方法：
雄性SPF级SD大鼠90只,根据体重,随机分成9组(n=9)。同时,采用香烟熏结合气管内滴注脂多糖的方法建立COPD大鼠模型。
具体实验分组及用药如下：
①益气法组：给予益气组中药汤剂灌胃
②活血法组：给予活血组中药汤剂灌胃
③化痰法组：给予化痰组中药汤剂灌胃
④益气活血法组：给予益气活血组中药汤剂灌胃
⑤益气化痰法组：给予益气化痰组中药汤剂灌胃
⑥活血化痰法组：给予活血化痰组中药汤剂灌胃
⑦益气活血化痰法组：给予益气活血化痰组中药汤剂灌胃
⑧模型组：给予生理盐水灌胃
⑨空白组：给予生理盐水灌胃
给药时间及次数：各组从造模后第四天开始起给药,每日一次,直至造模结束第5天,用药共30天。
给药结束后,取材。采用细胞计数和HE染色法测量不同组别之间BALF中白细胞数量以及中性粒细胞、巨噬细胞和淋巴细胞的百分比,同时应用ELISA方法测定BALF中细胞因子IL-8和TNF-a的含量；免疫组化方法测量肺组织u-PA、TGF-p1和Elastin蛋白表达；显微镜下观测肺组织结构变化,并结合图像分析仪测量支气管总管壁和平滑肌厚度的改变。
研究结果：
1.各组BALF炎性细胞和细胞因子的变化
各组白细胞计数,巨噬细胞、中性粒细胞和淋巴细胞百分比,细胞因子IL-8和TNF-a的含量相比较,结果显示：白细胞计数,巨噬细胞、中性粒细胞百分比,细胞因子IL-8和TNF-a含量存在统计学意义(F=121.04, P=0.000<0.05; F=64.97, P=0.000<0.05; F=77.83, P=0.000<0.05; F=23.4, P=0.000<0.05; F=17.2, P=0.000<0.05),淋巴细胞不存在统计学意义(F=0.74,P=0.653>0.05)。各组之间白细胞计数、巨噬细胞、中性粒细胞百分比,细胞因子IL-8和TNF-α含量两两比较结果显示：模型组与空白组、益气活血化痰组、活血化痰组、益气活血组、益气化痰组和活血组比较；空白组同益气活血化痰组、活血化痰组、益气活血组、益气化痰组、化痰组、活血组及益气组相比较；益气活血化痰组同益气组、化痰组、活血组及益气化痰组相比较；益气活血组、活血化痰组同益气组、化痰组、活血组相比较；益气化痰组、活血组同益气组和化痰组相比较,白细胞计数,巨噬细胞百分比和中性粒细胞百分比,以及细胞因子IL-8和TNF-α含量,有明显差异,具有统计学意义(P<0.05)；但是益气活血化痰组、活血化痰组及益气活血组相比较,益气化痰组和活血组相比较,模型组、益气组及化痰组相比较,白细胞计数、巨噬细胞百分比和中性粒细胞百分比,细胞因子IL-8和TNF-α含量无明显差异(P>0.05)。
2.各组肺组织病理结构改变和支气管总管壁及平滑肌厚度的变化
HE染色观察各组形态学变化：正常对照组气道壁薄,气道平滑肌薄；气管粘膜上皮排列规整,无脱落、粘膜上皮纤毛完整,排列整齐、管壁平滑、官腔无狭窄；未见杯状细胞增生及鳞状上皮化生；肺泡形态正常,间隔完整；未见炎症细胞。模型组显示：支气管黏膜上皮纤毛粘连、倒伏,部分气道有脱落；上皮细胞变性、坏死；出现鳞状上皮化生；杯状细胞数量增加；气道粘膜下腺体肥大增生,出现浆液腺泡粘液腺化生,部分支气管黏膜及腺体出现萎缩;小气道管腔狭窄；支气管壁充血水肿,有淋巴细胞和浆细胞浸润,并有管壁淋巴小结形成；肺泡扩张,出现间隔变窄破裂；气道壁增厚,气道平滑肌的厚度和正常组比较增厚明显。除益气组和化痰组外,其余各治疗组与模型组相比较,肺组织结构较好,炎症浸润较轻,气道壁增厚、气道平滑肌厚度减轻。且改善程度同模型组相比较由低到高分别为：活血组、益气化痰组、益气活血组、活血化痰组、益气活血化痰组。
图像分析结果显示：各组支气管总管壁厚度和平滑肌厚度,结果显示都存在统计学意义(F=133.6,P=0.000<0.05；F=65.6,P=0.000<0.05)。各组之间支气管总管壁厚度和平滑肌厚度两两比较结果显示：模型组、益气组和化痰组同空白组、益气活血化痰组、活血化痰组、益气活血组、益气化痰组和活血组比较；益气活血化痰组、活血化痰组、益气活血组、益气化痰组及活血组同空白组相比较；活血组同和益气活血组、活血化痰组及益气化痰活血组相比较；益气化痰组同益气化痰活血组相比较,前者支气管总管壁厚度和平滑肌厚度增厚,差异有显著性,具有统计学意义(P<0.05)；但是益气活血化痰组、活血化痰组及益气活血组相比较,益气化痰组和活血组相比较,模型组、益气组及化痰组相比较,支气管总管壁厚度和平滑肌厚度无明显差异(P>0.05)。
3.各组肺组织u-PA、TGF-p1和Elastin表达的变化
采用Kruskal Wallis Test统计方法分析各组肺组织u-PA、TGF-β1和Elastin蛋白表达的变化,结果显示：各组肺组织u-PA、TGF-p1和Elastin蛋白表达,有明显差异,存在统计学意义(P=0.000<0.05)。各组之间肺组织u-PA、TGD-β1和Elastin蛋白表达两两比较结果显示：模型组、益气组及化痰组与正常对照组、益气活血化痰组、活血化痰组、益气活血组、益气化痰组及活血组相比较；益气化痰组及活血组同空白组相比较；活血组同和益气活血组、活血化痰组及益气化痰活血组相比较；益气化痰组同益气化痰活血组相比较,u-PA和TGF-β1蛋白表达增强,Elastin蛋白表达降低,,差异有显著性,具有统计学意义(P<0.05)；但是益气活血化痰组、活血化痰组及益气活血组相比较；益气化痰组和活血组相比较；模型组、益气组及化痰组相比较,u-PA、 TGF-β1和Elastin蛋白表达无明显差异(P>0.05)。
研究结论：
1.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可以抑制COPD大鼠BALF中性粒细胞聚集和巨噬细胞的增多和活化,减少细胞因子IL-8和TNF-α的分泌,达到缓解炎症反应的疗效。
2.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可以抑制COPD大鼠肺组织u-PA和TGF-β1表达的同时,增强Elastin表达。
3.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可以改善COPD大鼠支气管总管壁和平滑肌的厚度。
4.具有益气活血化痰、活血化痰、益气活血、益气化痰及活血功效的中药可能是通过调节COPD大鼠肺组织u-PA、TGF-β1和Elastin的表达,达到干预和延缓COPD气道重塑的进程。
5.以益气、活血、化痰为主的三种治疗方法中,活血法更具疗效。
6.益气活血化痰组、活血化痰组和益气活血组的功效优于益气化痰组和活血组。
Objective:
To observe the intervention effect of Supplementing Qi, activating blood circulation, resolving phlegm and its combination regimens on airway inflammation and airway remodeling of COPD rats from the aspect of cytology, molecular biology and pathology. Through comparing and evaluating the efficacy of different treatment methods, we explore its possible mechanism action, and provide effective and reliable experimental basis for TCM on COPD.
Method:
90SD male rats were randomly divided into nine groups, meantime COPD rat model was established by intratracheal instillation of LPS and exposure to cigarette smoking daily. Specific subgroups and delivery are as follows:
①Supplementing Qi group:Administrated by decoction of supplementing Qi
②Activating blood circulation group:Administrated by decoction of activating blood circulation
③Resolving phlegm group:Administrated by decoction of resolving phlegm
④Supplementing Qi and activating blood circulation group:Administrated by decoction of Supplementing Qi and activating blood circulation
⑤Supplementing Qi and resolving phlegm group:Administrated by decoction of Supplementing Qi and resolving phlegm
⑥Activating blood circulation and resolving phlegm group:Administrated by decoction of activating blood circulation and resolving phlegm
⑦Supplementing Qi, activating blood circulation and resolving phlegm group: Administrated by decoction of Supplementing Qi, activating blood circulation and resolving phlegm
⑧The model group:Administrated by physiological saline
⑨The normal group:Administrated by physiological saline
Each group was administrated from the fourth day of molding, once a day, medication for30days.
Using cell counting and HE staining method to measure white blood cell count and the percentage of neutrophil, macrophage and lymphocyte in BALF, ELISA method to measure the content of cytokine IL-8and TNF-α in BALF, immunohistochemical method to measure the protein expression of u-PA, TGF-β1and Elastin in lung tissue, to observe the pulmonary tissue structural changes under the microscope, and measure the thickness of bronchial duct wall and smooth muscle with image analyzer.
Result:
1. The changes of inflammatory cells and cytokines in BALF
There was significant difference in different groups in white blood cell count,the percentage of neutrophil, macrophage and lymphocyte, and the content of cytokine IL-8and TNF-α in BALF (F=121.04, P=0.000<0.05; F=64.97, P=0.000<0.05; F=77.83, P=0.000<0.05; F=23.4, P=0.000<0.05; F=17.2, P=0.000<0.05). There was no significant difference in different groups in lymphocyte (F=0.74, P=0.653>0.05). The comparison of each two groups in white blood cell count,the percentage of neutrophil, macrophage and lymphocyte, and the content of cytokine IL-8and TNF-α in BALF show:the model group comparison with control group, supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; the control group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group, resolving phlegm group, and supplementing Qi group; supplementing Qi, activating blood circulation and resolving phlegm group comparison with activating blood circulation group, resolving phlegm group, supplementing Qi group, and supplementing Qi and resolving phlegm group; supplementing Qi and activating blood circulation group,activating blood circulation and resolving phlegm group comparison with activating blood circulation group, resolving phlegm group, supplementing Qi group; supplementing Qi and resolving phlegm group and activating blood circulation group comparison with resolving phlegm group and supplementing Qi group, there was significant difference (P<0.05). But comparison among supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, and supplementing Qi and activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood; the model group, resolving phlegm group, and supplementing Qi group was no significant difference (P>0.05).
2. The thickness changes of bronchial duct wall and smooth muscle
The morphologic changes of lung:the control group was normal, while the model group was showed significant pathological changes in the lung. While the other group except for resolving phlegm group, and supplementing Qi group, was improved in different level. The level of improvement from high to low was supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group.
The statistical results show:There was significant difference in different groups in the thickness of bronchial duct wall and smooth muscle (F=133.6, P=0.000<0.05; F=65.6, P=0.000<0.05). The comparison of each two groups in the thickness of bronchial duct wall and smooth muscle show:the model group, supplementing Qi group and resolving phlegm group comparison with control group, supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; the control group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; activating blood circulation group comparison with supplementing Qi and activating blood circulation group, activating blood circulation and resolving phlegm group, supplementing Qi, activating blood circulation and resolving phlegm group; supplementing Qi and resolving phlegm group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, there was significant difference (P<0.05). But comparison among supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, and supplementing Qi and activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood; the model group, resolving phlegm group, and supplementing Qi group was no significant difference (P>0.05).
3. The changes of protein expression of u-PA, TGF-β1and Elastin in lung tissue
The statistical results show:There was significant difference in different groups in the protein expression of u-PA, TGF-β1and Elastin of lung tissue (P=0.000<0.05). The comparison of each two groups in the protein expression of u-PA, TGF-β1and Elastin of lung tissue show:the model group, supplementing Qi group and resolving phlegm group comparison with control group, supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and resolving phlegm group, supplementing Qi and activating blood circulation group, activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood circulation group comparison with the control group; activating blood circulation group comparison with supplementing Qi and activating blood circulation group, activating blood circulation and resolving phlegm group, supplementing Qi, activating blood circulation and resolving phlegm group; supplementing Qi and resolving phlegm group comparison with supplementing Qi, activating blood circulation and resolving phlegm group, there was significant difference (P<0.05). But comparison among supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, and supplementing Qi and activating blood circulation group; supplementing Qi and resolving phlegm group and activating blood; the model group, resolving phlegm group, and supplementing Qi group was no significant difference (P>0.05).
Conclusion:
1. The management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can inhibit accumulation, increase and activation of neutrophil and macrophage, reduce secretion of cytokine IL-8and TNF-α of BALF, and then relieve inflammation of COPD rat.
2. The management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can inhibit the expression of u-PA and TGF-β1,meanwhile enhance the expression of elastin in COPD rat lung tissue.
3. The management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can reduce thickening trend of bronchial duct wall and smooth muscle.
4. Tthe management of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm, Supplementing Qi and resolving phlegm, Supplementing Qi and activating blood circulation, activating blood circulation can intervent and delay COPD airway remodeling process, which maybe through the regulation of the expression of u-PA, TGF-β1and elastin in COPD rat lung tissue.
5. Activating blood circulation group was effective comparing with resolving phlegm group and supplementing Qi group.
6. The effect of supplementing Qi, activating blood circulation and resolving phlegm group, activating blood circulation and resolving phlegm group, supplementing Qi and activating blood circulation group is better than supplementing Qi and resolving phlegm group and activating blood circulation group.
引文
[1]Murray CJL, Lopez AD. Evidence-based health policy-lessons from the global burden of disease study[J]. Science 1996,274:740-743.
[2]陈斯宁,黄美杏,古立新,等.清肺化痰颗粒治疗慢性阻塞性肺疾病急性加重期痰热郁肺证临床观察[J].广西中医药,2007,30(1)：8-10.
[3]荆小莉,王东平,李慧.清热化痰对慢性阻塞性肺疾病急性发作患者氧化应激和炎症的影响[J].中华临床医师杂志,2009,3(4)：582-587.
[4]龚国良,李欣.痰热清治疗慢性阻塞性肺疾病急性加重期的临床疗效及细胞因子水平的研究[J].中国中药杂志,2009,34(1)：104-106.
[5]崔焱,梁直英,董竞成.活血化瘀方治疗慢性阻塞性肺疾病急性加重期的临床观察[J].中国中西医结合杂志,2005,25(4)：327.
[6]杭东辉,杨红娣.活血化瘀方对COPD急性加重期疗效影响源[J].中国中医急症,2007,16(12)：1455-1457.
[7]黄慧婷.化痰活血法治疗慢性阻塞性肺疾病急性加重期患者临床观察及其对血液流变学影响[D].广州中医药大学,2007.
[8]杨荣源,林燕凤,李际强.小青龙汤加减治疗慢性阻塞性肺病急性加重期临床观察[J].新中医,2009,41(6)：43.
[9]李建生,李素云,陈萍,等.燥湿化痰方药治疗慢性阻塞性肺疾病急性加重期痰湿壅肺证的临床疗效评价[J].辽宁中医杂志,2010,37(9)：1721-1724.
[10]王胜,季红燕,张念志.益肺健脾中药改善慢性阻塞性肺疾病患者肺功能及营养状况[J].中国临床康复,2005,9(31)：141-142.
[11]韩云,林燕钊,林琳.中医药在机械通气治疗慢性阻塞性肺疾病[J].中医杂志,2005,46(3)：223.
[12]张德邦.中医学对慢性阻塞性肺疾病的认识[J].中国中医急症,2009,18(12)：2000.
[13]吴伟平,陈清维,徐丽,等.六君子散煎对COPD缓解期营养状况及肺功能的影响[J].辽宁中医杂志,2009,36(4)：559-561.
[14]柳慧明.扶正固本汤治疗慢性阻塞性肺疾病62例[J].陕西中医,2008,29(9)：1191.
[15]崔淑芬,魏彬,郑云霞,等.益气化瘀法对慢阻肺缓解期患者血.液流变学的影响[J].江苏中医药,2008,40(4)：26-27.
[16]范长秋,蒋文凤.复方蛤蚧胶囊对慢性阻塞性肺疾病缓解期生活质量的影响[J].中国自然医学杂志,2008,10(4)：289-291.
[17]苏惠萍COPD稳定期的中医治疗思路及方法[J].中国全科医学,2009,12(8)：16.
[18]吴标.加味参蛤蚧散对慢阻肺缓解期患者肺通气功能临床观察[J].医药产业资讯,2006,3(3)：70.
[19]王文章,郑彩霞,张念志.穴位贴敷法治疗慢性阻塞性肺疾病90例临床观察[J].中国中医急症,2009,18(2)：186.
[20]齐昌菊.穴位敷贴对缓解期慢性阻塞性肺疾病患者生活质量的影响[J].上海中医药杂志,2010,44(4)：52.
[21]李素云,李建生,余学庆,等.舒肺贴治疗慢性阻塞性肺疾病疗效观察[J].陕西中医,2009,30(4)：391.
[22]石克华,折哲,熊必丹,等.咳喘散穴位敷贴治疗慢性阻塞性肺疾病稳定期疗效观察[J].世界中西医结合杂志,2009,4(3)：195.
[23]李菊莲,费新明,范娥.穴位贴敷法治疗慢性阻塞性肺疾病临床观察[J].针灸临床杂志,2009,25(4)：35.
[24]朱益敏.穴位注射黄芪注射液对COPD稳定期患者生活质量和肺功能的影响观察[J].中国实用医药,2008,3(35)：128.
[25]郑盛杰,戴勇,魏成功.喘可治穴位注射治疗慢性阻塞性肺疾病稳定期的临床疗效及其对IL-2,IL-10的影响[J].新中医,2006,38(7)：63.
[26]李克泉.雾化吸入药物治疗毛细支气管炎进展[J].江西医药,2009,44(7)：738.
[27]黄大文,李英姿,刘斌.中药制剂经氧气雾化吸入治疗慢性阻塞性肺病疗效观察[J].陕西中医学院学报,2003,26(4)：7.
[28]姜明全,曹忠良,项志兵,等.参麦注射液结合雾化吸入鱼腥草注射液治疗慢性阻塞性肺疾病急性加重期疗效观察[J].上海中医药杂志,2006,40(5)：11.
[29]黄玉明.中药液雾化吸入对慢性阻塞性肺疾病肺功能的影响[J].四川中医,2008,26(2)：53.
[30]陈钦,谢田钢,金先桥,等.推拿治疗慢性阻塞性肺疾病的疗效[J].中国临床康复,2006,10(7)：10.
[31]刘小红.点按肺腧结合拢唇呼气在慢性阻塞性肺病中的临床研究[J].按摩与导引,2005,21(6)：7.
[32]郭海英,张洪斌.中医社区康复方法在COPD缓解期患者康复中的应用[J].江苏中医,1999,20(10)：43-45.
[33]Holgate ST. Airway wall remodeling. Eur Respir Rev,2000,10(69):58-63.
[34]Di StefanoA, Caramori G, Ricciardolo FL, et al. Cellular and molecular mechanisms in chronic obstructive pulmonary disease:an overview[J]. Clin Exp Allergy,2004,34:1156-1167.
[35]Rytila P, Plataki M, Bucchieri F, et al. Airway neutrophilia in COPD is notassociated with increased neutrophil survival[J]. Eur Respir J,2006,28:1163-1169.
[36]Plataki M, Tzortzaki E, Rytila P, et al. Apoptotic mechanisms in the pathogenesis of COPD[J]. Int J Chron Obstruct Pulmon Dis,2006,1:161-171.
[37]PANTELIDIS PA, SOUTHCOTT AM, BLACKC M, et al. Up-regulation of IL-8 secretion by alveoilar macrophages from patients with fibrosis alveolitis, a subpopulation analysis[J]. Clin Exp Immunol,1997,108:95.
[38]Vernooy JH, Ku ukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease:soluble tumor necrosis factor receptors are increased in sputum[J]. Am J Respir Crit Care Med,2002,166:1218-1224.
[39]Parr DG, White AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD:a prospective descriptive study[J]. Respir Res,2006,18:136-146.
[40]董平,孔令敏,陈文靖,等.COPD急性发作期白介素-8、肿瘤坏死因子-α的表达与预后分析[J].中国厂矿医学,2002,15(2)：99.100.
[41]Louisia S, Masguclet A.C. The medial and inferior calcaneal nerves:an anatomic study [J]. Surgical Radiologic Anatomy,1999,21:169.
[42]Snider GL. Chronic obstructive pulmonary disease-a continuing challenge. Am Rev Respir Dis.1986,133(5):942-944.
[43]YAMAMOTO C, YONEDA T, YOSHIKAWA M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8[J]. Chest,1997,112:505-510.
[44]Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest.1992,89(5):1478-1484.
[45]费湘平,周玉皆.慢性阻塞性肺疾病气道重塑的研究现状.中华实用中西医杂志,2005,18(21)：1464-1466.
[46]Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med.1996,153(2):530-534.
[47]Gosset P, Tillie-Leblond I, Janin A, et al. Increased expression of ELAM-1, ICAM-1, and VCAM-1 on bronchial biopsies from allergic asthmatic patients. Ann NY Acad Sci,1994,725:163-72.
[48]Becker S, Koren HS, Henke DC. Interleukin-8 expression in normal nasal epithelium and its modulation by infection with respiratory syncytial virus and cytokines tumor necrosis factor, interleukin-1, and interleukin-6. Am J Respir Cell Mol Biol,1993,8(1):20-27.
[49]宋一平,崔德健,茅培英,等.慢性阻塞性肺疾病大鼠模型气道重建及生长因子的研究[J].中华结核和呼吸杂志,2001,24(5)：283-287.
[50]HELDIN C H, MIYAZONO K, ten-DIJKE P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins[J]. Nature,1997,390(6659):465-471.
[51]Black PN, Young PG, Skinner SJ. Response of airway smooth muscle cells to TGF-beta 1:effects on growth and synthesis of glucosaminoglycans. Am J Physiol.1996,271(6 Pt 1):L910-917.
[52]李广虎,李志平.TGF-β1信号转导在放射性肺纤维化形成中的作用和意义[J].中华放射学与防 护杂志,2005,25(1)：97-99.
[53]Lee MS, Gu D, Feng L, et al. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic Production of growth transforming factor-betal. Am J Pathol,1995, (4): 42-52.
[54]Aubert JD, Dalal BI, Bai TR, et al. Transforming growth factor beta 1 gene expression in human airways. Thorax,1994,49:225-232.
[55]VignolaAM, Chanez P, Chiappara G, et al.Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med.1997,156:591-599.
[56]VignolaAM, Chanez P, Chiappara G, et al.Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases.Clin Exp Immunol,1996,106:114-119.
[57]周廷冲主编.多肽生长因子基础与临床.北京.中国科学科技出版社,1992：85.
[58]Redingtom AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med.1997,156:642-647.
[59]HoshinoM, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrixmetallo Proteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol,1998,102: 783-788.
[60]Kelly EA, Busse WW, Jarjour NN, et al. Inereased matrixmetallo Proteinase-9 in the airway after allergen challenge. Am J Respir Cirt Care Med,2000,162:1157-1161.
[61]Vignola AM, SPringall D, Vignola AM, et al. Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med,1998,158:1945-1950.
[62]周向东,黄勇.急性肺损伤时肺血管床中性粒细胞滞留的分子基础[J].中华内科杂志,1996,35(8)：556.
[63]Inomata S, Takahashi H, Nagata M, et al. Acute lung injurys an adverse event of gefitinib[J]. Anticancer Drugs,2004,15:461-467.
[64]湘杭,廖二元,周后德,等.雌二醇对人成骨样细胞基质金属蛋白酶及其抑制因子的作用[J].中华内科杂志,2000,39：243-246.
[65]张念志,李泽庚,季红燕,等.参七虫草胶囊对慢性阻塞性肺疾病大鼠模型内皮素和一氧化氮水平的影响[J].中国实验方剂学杂志,2006,12(10)：39-40.
[66]黄礼明.试论痰、瘀、虚在慢性阻塞性肺疾病辨治中的重要性[J].贵阳中医学院学报,2000,22(1)：5-7.
[67]王新华.徐志瑛治疗慢性阻塞性肺病的经验[J].浙江中医学院学报,2000,24(4)：56.
[68]符思.浅谈从虚、瘀辨治慢性阻塞性肺气肿[J].安徽中医学院学报,1996,15(2)：39.
[69]林育华.活血化瘀法治疗慢阻肺95例临床观察[J].新中医,1998,30(2)：33.
[70]吴其标,李素云,马利军,等.益气养阴活血化痰法对COPD稳定期免疫功能的影响[J].长春中医学院学报,2001,17(6)：10-11.
[71]李兴文,戴路明,黄维丽,等.云南白药对稳定期COPD痰液细胞因子调控的研究[J].昆明医学院学报,2001,6(2)：29-31.
[72]谢纬,熊广,韩正雪.参蛤散对COPD大鼠血清细胞因子IL-8、TNF-α的影响[J].中国老年保健医学,2009,7(2)：108-109.
[73]杨月,侯继中,池红井,等.黄芪对慢性阻塞性肺病大鼠气道炎症干预作用实验研究[J].山东医药,2010,50(20)：49-51.
[74]谭玉萍,王朝晖,蒙定水,等.银杏叶提取物可抑制慢性阻塞性肺疾病大鼠气道及肺血管重塑[J].中国呼吸与危重监护杂志,2008,7(4)：274-276.
[75]李金田,田永衍,梁晶,等.芪蛭皱肺无糖颗粒对COPD大鼠模型呼吸功能和肺组织形态影响的实验研究[J].北京中医药,2009,28(5)：380-383.
[76]张伟,肖惠珍,苗倩.强肌健力方对肺脾两虚型COPD大鼠气道壁厚度和转移生长因子β1的影响[J].辽宁中医杂志,2009,36(4)：638-640.
[77]朱慧志,韩明向,李泽庚,等.补肺通络方对慢性阻塞性肺疾病模型大鼠的保护作用[J].中国临床保健杂志,2010,13(4)：374-377.
[78]禹志领.保元汤研究概况[J].时珍国医药,1999,10(5)：379-381.
[79]汪德清,沈文海,田亚平,等.黄芪活性提取成份对膜脂质过氧化损伤的防护作用[J].中国中药杂志,1996,(2112)：746-747.
[80]田风军,陈亚丽,何秀月,等.黄芪注射液治疗心力衰竭疗效观察[J].河北中西医结合杂志,1997,6(3)：45-61.
[81]杨月,侯继中,池红井,等.黄芪对慢性阻塞性肺病大鼠气道炎症干预作用实验研究[J].山东医药,2010,50(20)：49-51.
[82]谢鸣主编.中医方剂现代研究(下卷).学苑出版社,1997,1：1482.
[83]王伟.苍术二陈汤加减治疗COPD的临床观察[J].中国中医药咨讯,2011,3(12)：80.
[84]刘小平,王贤成.加味二陈汤治疗慢性阻塞性肺病急性加重期疗效观察[J].浙江中医药大学学报,2009,33(1)：78-79.
[85]蔡冠球.肺系疾病的中西医治疗理论探讨[J].上海中医药杂志,1994,28(2)：20-21.
[86]王良兴.川芎嗪对组胺和乙酰胆碱所致豚鼠气管条收缩作用的影响[J].温州医学院学报,1995,25(3)：158.
[87]刘忠,李永春.川芎嗪对慢性阻塞性肺疾病大鼠模型白细胞介素-8的影响[J].中国中医急症,2008,17(5)：652-654.
[88]金摇翔,时摇乐,汀珊珊,等.桃红四物汤不同提取部位对血虚血瘀型大鼠微循环的影响[J].安徽医药,2010,14(4)：387-389.
[89]徐摇立,时摇乐,李摇祥,等.加减桃红四物汤醇提物对寒凝血瘀模型小鼠微循环和凝血时间的影响[J].江苏中医药,2008,40(11)：121-122.
[90]谢摇辉,罗尧岳,周小青,等.血府逐瘀汤及其拆方对动脉粥样硬化兔血脂、血流动力学的影 响[J].湖南中医药大学学报,2008,28(2)：13-15.
[91]李元聪,韦从云,伍眷华.桃红四物汤加味对兔复发性口腔溃疡中内皮素-1的表达及与血瘀证的相关性研究[J].湖南中医学院学报,2005,25(6)：12-15.
[92]白敬华,王惠兰.益气活血对慢性阻塞性肺疾病血液流变学及血瘀证的影响[J].甘肃中医学院学报,1996,13(4)：4.
[93]姚红军.生脉二陈汤配合西药治疗慢性肺源性心脏病52例疗效观察[J].实用中西医结合临床,2009,9(1)：18-19.
[94]郭素芬.丹红注射液合二陈汤加昧治疗慢性阻塞性肺疾病疗效观察[J].中国社区医师.医学专业,2011,28(13)：153.
[95]王冬秀.桃红二陈汤加速肺部罗音吸收的临床应用[J].江西中医学院学报,1994,6(2)：25.
[96]冯永庆.桃红二陈汤促进肺部水泡音吸收作用观察[J].中级医师,1996,31(12)：46.
[97]王琦,武维屏,田秀英,等.益气活血化痰法治疗肺胀的临床研究[J].北京中医药大学学报,1994,17(6)：44-46.
[98]刘洪,张弛.慢性阻塞性肺疾病气管炎症与细胞因子水平变化的研究[J]. Clincal Medicine of China.2004,20(4):323-324.
[99]Xiao W, Hsu YP, Ishizaka A, et al. Sputum cathelicindin, uokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis COPD and asthma inflammation. Chest,2005, 128:2316-2326.
[100]肖伟,童文玲,马德东.慢性阻塞性肺疾病患者气道尿激酶型纤溶酶原激活物系统成分的高水平状态[J].中华结核和呼吸杂志,2006,29(11)：723-726.
[101]Coutts A, Chen G, Stephens N, et al. Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen. Am J Physiol Lung Cell Mol Physiol,2001,280: L999-1008.
[2]陈斯宁,黄美杏,古立新,等.清肺化痰颗粒治疗慢性阻塞性肺疾病急性加重期痰热郁肺证临床观察[J].广西中医药,2007,30(1)：8-10.
[3]荆小莉,王东平,李慧.清热化痰对慢性阻塞性肺疾病急性发作患者氧化应激和炎症的影响[J].中华临床医师杂志,2009,3(4)：582-587.
[4]龚国良,李欣.痰热清治疗慢性阻塞性肺疾病急性加重期的临床疗效及细胞因子水平的研究[J].中国中药杂志,2009,34(1)：104-106.
[5]崔焱,梁直英,董竞成.活血化瘀方治疗慢性阻塞性肺疾病急性加重期的临床观察[J].中国中西医结合杂志,2005,25(4)：327.
[6]杭东辉,杨红娣.活血化瘀方对COPD急性加重期疗效影响源[J].中国中医急症,2007,16(12)：1455-1457.
[7]黄慧婷.化痰活血法治疗慢性阻塞性肺疾病急性加重期患者临床观察及其对血液流变学影响[D].广州中医药大学,2007.
[8]杨荣源,林燕凤,李际强.小青龙汤加减治疗慢性阻塞性肺病急性加重期临床观察[J].新中医,2009,41(6)：43.
[9]李建生,李素云,陈萍,等.燥湿化痰方药治疗慢性阻塞性肺疾病急性加重期痰湿壅肺证的临床疗效评价[J].辽宁中医杂志,2010,37(9)：1721-1724.
[10]王胜,季红燕,张念志.益肺健脾中药改善慢性阻塞性肺疾病患者肺功能及营养状况[J].中国临床康复,2005,9(31)：141-142.
[11]韩云,林燕钊,林琳.中医药在机械通气治疗慢性阻塞性肺疾病[J].中医杂志,2005,46(3)：223.
[12]张德邦.中医学对慢性阻塞性肺疾病的认识[J].中国中医急症,2009,18(12)：2000.
[13]吴伟平,陈清维,徐丽,等.六君子散煎对COPD缓解期营养状况及肺功能的影响[J].辽宁中医杂志,2009,36(4)：559-561.
[14]柳慧明.扶正固本汤治疗慢性阻塞性肺疾病62例[J].陕西中医,2008,29(9)：1191.
[15]崔淑芬,魏彬,郑云霞,等.益气化瘀法对慢阻肺缓解期患者血.液流变学的影响[J].江苏中医药,2008,40(4)：26-27.
[16]范长秋,蒋文凤.复方蛤蚧胶囊对慢性阻塞性肺疾病缓解期生活质量的影响[J].中国自然医学杂志,2008,10(4)：289-291.
[17]苏惠萍COPD稳定期的中医治疗思路及方法[J].中国全科医学,2009,12(8)：16.
[18]吴标.加味参蛤蚧散对慢阻肺缓解期患者肺通气功能临床观察[J].医药产业资讯,2006,3(3)：70.
[19]王文章,郑彩霞,张念志.穴位贴敷法治疗慢性阻塞性肺疾病90例临床观察[J].中国中医急症,2009,18(2)：186.
[20]齐昌菊.穴位敷贴对缓解期慢性阻塞性肺疾病患者生活质量的影响[J].上海中医药杂志,2010,44(4)：52.
[21]李素云,李建生,余学庆,等.舒肺贴治疗慢性阻塞性肺疾病疗效观察[J].陕西中医,2009,30(4)：391.
[22]石克华,折哲,熊必丹,等.咳喘散穴位敷贴治疗慢性阻塞性肺疾病稳定期疗效观察[J].世界中西医结合杂志,2009,4(3)：195.
[23]李菊莲,费新明,范娥.穴位贴敷法治疗慢性阻塞性肺疾病临床观察[J].针灸临床杂志,2009,25(4)：35.
[24]朱益敏.穴位注射黄芪注射液对COPD稳定期患者生活质量和肺功能的影响观察[J].中国实用医药,2008,3(35)：128.
[25]郑盛杰,戴勇,魏成功.喘可治穴位注射治疗慢性阻塞性肺疾病稳定期的临床疗效及其对IL-2,IL-10的影响[J].新中医,2006,38(7)：63.
[26]李克泉.雾化吸入药物治疗毛细支气管炎进展[J].江西医药,2009,44(7)：738.
[27]黄大文,李英姿,刘斌.中药制剂经氧气雾化吸入治疗慢性阻塞性肺病疗效观察[J].陕西中医学院学报,2003,26(4)：7.
[28]姜明全,曹忠良,项志兵,等.参麦注射液结合雾化吸入鱼腥草注射液治疗慢性阻塞性肺疾病急性加重期疗效观察[J].上海中医药杂志,2006,40(5)：11.
[29]黄玉明.中药液雾化吸入对慢性阻塞性肺疾病肺功能的影响[J].四川中医,2008,26(2)：53.
[30]陈钦,谢田钢,金先桥,等.推拿治疗慢性阻塞性肺疾病的疗效[J].中国临床康复,2006,10(7)：10.
[31]刘小红.点按肺腧结合拢唇呼气在慢性阻塞性肺病中的临床研究[J].按摩与导引,2005,21(6)：7.
[32]郭海英,张洪斌.中医社区康复方法在COPD缓解期患者康复中的应用[J].江苏中医,1999,20(10)：43-45.
[33]Holgate ST. Airway wall remodeling. Eur Respir Rev,2000,10(69):58-63.
[34]Di StefanoA, Caramori G, Ricciardolo FL, et al. Cellular and molecular mechanisms in chronic obstructive pulmonary disease:an overview[J]. Clin Exp Allergy,2004,34:1156-1167.
[35]Rytila P, Plataki M, Bucchieri F, et al. Airway neutrophilia in COPD is notassociated with increased neutrophil survival[J]. Eur Respir J,2006,28:1163-1169.
[36]Plataki M, Tzortzaki E, Rytila P, et al. Apoptotic mechanisms in the pathogenesis of COPD[J]. Int J Chron Obstruct Pulmon Dis,2006,1:161-171.
[37]PANTELIDIS PA, SOUTHCOTT AM, BLACKC M, et al. Up-regulation of IL-8 secretion by alveoilar macrophages from patients with fibrosis alveolitis, a subpopulation analysis[J]. Clin Exp Immunol,1997,108:95.
[38]Vernooy JH, Ku ukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease:soluble tumor necrosis factor receptors are increased in sputum[J]. Am J Respir Crit Care Med,2002,166:1218-1224.
[39]Parr DG, White AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD:a prospective descriptive study[J]. Respir Res,2006,18:136-146.
[40]董平,孔令敏,陈文靖,等.COPD急性发作期白介素-8、肿瘤坏死因子-α的表达与预后分析[J].中国厂矿医学,2002,15(2)：99.100.
[41]Louisia S, Masguclet A.C. The medial and inferior calcaneal nerves:an anatomic study [J]. Surgical Radiologic Anatomy,1999,21:169.
[42]Snider GL. Chronic obstructive pulmonary disease-a continuing challenge. Am Rev Respir Dis.1986,133(5):942-944.
[43]YAMAMOTO C, YONEDA T, YOSHIKAWA M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8[J]. Chest,1997,112:505-510.
[44]Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest.1992,89(5):1478-1484.
[45]费湘平,周玉皆.慢性阻塞性肺疾病气道重塑的研究现状.中华实用中西医杂志,2005,18(21)：1464-1466.
[46]Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med.1996,153(2):530-534.
[47]Gosset P, Tillie-Leblond I, Janin A, et al. Increased expression of ELAM-1, ICAM-1, and VCAM-1 on bronchial biopsies from allergic asthmatic patients. Ann NY Acad Sci,1994,725:163-72.
[48]Becker S, Koren HS, Henke DC. Interleukin-8 expression in normal nasal epithelium and its modulation by infection with respiratory syncytial virus and cytokines tumor necrosis factor, interleukin-1, and interleukin-6. Am J Respir Cell Mol Biol,1993,8(1):20-27.
[49]宋一平,崔德健,茅培英,等.慢性阻塞性肺疾病大鼠模型气道重建及生长因子的研究[J].中华结核和呼吸杂志,2001,24(5)：283-287.
[50]HELDIN C H, MIYAZONO K, ten-DIJKE P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins[J]. Nature,1997,390(6659):465-471.
[51]Black PN, Young PG, Skinner SJ. Response of airway smooth muscle cells to TGF-beta 1:effects on growth and synthesis of glucosaminoglycans. Am J Physiol.1996,271(6 Pt 1):L910-917.
[52]李广虎,李志平.TGF-β1信号转导在放射性肺纤维化形成中的作用和意义[J].中华放射学与防 护杂志,2005,25(1)：97-99.
[53]Lee MS, Gu D, Feng L, et al. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic Production of growth transforming factor-betal. Am J Pathol,1995, (4): 42-52.
[54]Aubert JD, Dalal BI, Bai TR, et al. Transforming growth factor beta 1 gene expression in human airways. Thorax,1994,49:225-232.
[55]VignolaAM, Chanez P, Chiappara G, et al.Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med.1997,156:591-599.
[56]VignolaAM, Chanez P, Chiappara G, et al.Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases.Clin Exp Immunol,1996,106:114-119.
[57]周廷冲主编.多肽生长因子基础与临床.北京.中国科学科技出版社,1992：85.
[58]Redingtom AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med.1997,156:642-647.
[59]HoshinoM, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrixmetallo Proteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol,1998,102: 783-788.
[60]Kelly EA, Busse WW, Jarjour NN, et al. Inereased matrixmetallo Proteinase-9 in the airway after allergen challenge. Am J Respir Cirt Care Med,2000,162:1157-1161.
[61]Vignola AM, SPringall D, Vignola AM, et al. Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med,1998,158:1945-1950.
[62]周向东,黄勇.急性肺损伤时肺血管床中性粒细胞滞留的分子基础[J].中华内科杂志,1996,35(8)：556.
[63]Inomata S, Takahashi H, Nagata M, et al. Acute lung injurys an adverse event of gefitinib[J]. Anticancer Drugs,2004,15:461-467.
[64]湘杭,廖二元,周后德,等.雌二醇对人成骨样细胞基质金属蛋白酶及其抑制因子的作用[J].中华内科杂志,2000,39：243-246.
[65]张念志,李泽庚,季红燕,等.参七虫草胶囊对慢性阻塞性肺疾病大鼠模型内皮素和一氧化氮水平的影响[J].中国实验方剂学杂志,2006,12(10)：39-40.
[66]黄礼明.试论痰、瘀、虚在慢性阻塞性肺疾病辨治中的重要性[J].贵阳中医学院学报,2000,22(1)：5-7.
[67]王新华.徐志瑛治疗慢性阻塞性肺病的经验[J].浙江中医学院学报,2000,24(4)：56.
[68]符思.浅谈从虚、瘀辨治慢性阻塞性肺气肿[J].安徽中医学院学报,1996,15(2)：39.
[69]林育华.活血化瘀法治疗慢阻肺95例临床观察[J].新中医,1998,30(2)：33.
[70]吴其标,李素云,马利军,等.益气养阴活血化痰法对COPD稳定期免疫功能的影响[J].长春中医学院学报,2001,17(6)：10-11.
[71]李兴文,戴路明,黄维丽,等.云南白药对稳定期COPD痰液细胞因子调控的研究[J].昆明医学院学报,2001,6(2)：29-31.
[72]谢纬,熊广,韩正雪.参蛤散对COPD大鼠血清细胞因子IL-8、TNF-α的影响[J].中国老年保健医学,2009,7(2)：108-109.
[73]杨月,侯继中,池红井,等.黄芪对慢性阻塞性肺病大鼠气道炎症干预作用实验研究[J].山东医药,2010,50(20)：49-51.
[74]谭玉萍,王朝晖,蒙定水,等.银杏叶提取物可抑制慢性阻塞性肺疾病大鼠气道及肺血管重塑[J].中国呼吸与危重监护杂志,2008,7(4)：274-276.
[75]李金田,田永衍,梁晶,等.芪蛭皱肺无糖颗粒对COPD大鼠模型呼吸功能和肺组织形态影响的实验研究[J].北京中医药,2009,28(5)：380-383.
[76]张伟,肖惠珍,苗倩.强肌健力方对肺脾两虚型COPD大鼠气道壁厚度和转移生长因子β1的影响[J].辽宁中医杂志,2009,36(4)：638-640.
[77]朱慧志,韩明向,李泽庚,等.补肺通络方对慢性阻塞性肺疾病模型大鼠的保护作用[J].中国临床保健杂志,2010,13(4)：374-377.
[78]禹志领.保元汤研究概况[J].时珍国医药,1999,10(5)：379-381.
[79]汪德清,沈文海,田亚平,等.黄芪活性提取成份对膜脂质过氧化损伤的防护作用[J].中国中药杂志,1996,(2112)：746-747.
[80]田风军,陈亚丽,何秀月,等.黄芪注射液治疗心力衰竭疗效观察[J].河北中西医结合杂志,1997,6(3)：45-61.
[81]杨月,侯继中,池红井,等.黄芪对慢性阻塞性肺病大鼠气道炎症干预作用实验研究[J].山东医药,2010,50(20)：49-51.
[82]谢鸣主编.中医方剂现代研究(下卷).学苑出版社,1997,1：1482.
[83]王伟.苍术二陈汤加减治疗COPD的临床观察[J].中国中医药咨讯,2011,3(12)：80.
[84]刘小平,王贤成.加味二陈汤治疗慢性阻塞性肺病急性加重期疗效观察[J].浙江中医药大学学报,2009,33(1)：78-79.
[85]蔡冠球.肺系疾病的中西医治疗理论探讨[J].上海中医药杂志,1994,28(2)：20-21.
[86]王良兴.川芎嗪对组胺和乙酰胆碱所致豚鼠气管条收缩作用的影响[J].温州医学院学报,1995,25(3)：158.
[87]刘忠,李永春.川芎嗪对慢性阻塞性肺疾病大鼠模型白细胞介素-8的影响[J].中国中医急症,2008,17(5)：652-654.
[88]金摇翔,时摇乐,汀珊珊,等.桃红四物汤不同提取部位对血虚血瘀型大鼠微循环的影响[J].安徽医药,2010,14(4)：387-389.
[89]徐摇立,时摇乐,李摇祥,等.加减桃红四物汤醇提物对寒凝血瘀模型小鼠微循环和凝血时间的影响[J].江苏中医药,2008,40(11)：121-122.
[90]谢摇辉,罗尧岳,周小青,等.血府逐瘀汤及其拆方对动脉粥样硬化兔血脂、血流动力学的影 响[J].湖南中医药大学学报,2008,28(2)：13-15.
[91]李元聪,韦从云,伍眷华.桃红四物汤加味对兔复发性口腔溃疡中内皮素-1的表达及与血瘀证的相关性研究[J].湖南中医学院学报,2005,25(6)：12-15.
[92]白敬华,王惠兰.益气活血对慢性阻塞性肺疾病血液流变学及血瘀证的影响[J].甘肃中医学院学报,1996,13(4)：4.
[93]姚红军.生脉二陈汤配合西药治疗慢性肺源性心脏病52例疗效观察[J].实用中西医结合临床,2009,9(1)：18-19.
[94]郭素芬.丹红注射液合二陈汤加昧治疗慢性阻塞性肺疾病疗效观察[J].中国社区医师.医学专业,2011,28(13)：153.
[95]王冬秀.桃红二陈汤加速肺部罗音吸收的临床应用[J].江西中医学院学报,1994,6(2)：25.
[96]冯永庆.桃红二陈汤促进肺部水泡音吸收作用观察[J].中级医师,1996,31(12)：46.
[97]王琦,武维屏,田秀英,等.益气活血化痰法治疗肺胀的临床研究[J].北京中医药大学学报,1994,17(6)：44-46.
[98]刘洪,张弛.慢性阻塞性肺疾病气管炎症与细胞因子水平变化的研究[J]. Clincal Medicine of China.2004,20(4):323-324.
[99]Xiao W, Hsu YP, Ishizaka A, et al. Sputum cathelicindin, uokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis COPD and asthma inflammation. Chest,2005, 128:2316-2326.
[100]肖伟,童文玲,马德东.慢性阻塞性肺疾病患者气道尿激酶型纤溶酶原激活物系统成分的高水平状态[J].中华结核和呼吸杂志,2006,29(11)：723-726.
[101]Coutts A, Chen G, Stephens N, et al. Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen. Am J Physiol Lung Cell Mol Physiol,2001,280: L999-1008.